A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

Clinical trial NCT07305974 · RECRUITING

Trial details

NCT number: NCT07305974
Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IgA Nephropathy (IgAN)

Start date: 2025-09-08
Primary completion: 2029-03-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.